Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity in the provided text. The company currently holds cash of INR 80 crores (both Thyrocare and ESL combined) primarily in debt mutual funds. The management has been cautious about bidding for new government contracts to manage billing risk, indicating a conservative financial approach. The focus appears to be on organic growth, partnership expansions, and capex investments (~INR 45 crores planned for FY '24), without reliance on new external fundraisings. No explicit discussion about equity dilution or new debt i

Any current/future capex/capital investment/strategic investment?

FY '23 capex was close to INR 40 crores. FY '24 capex budgeted around INR 45 crores. Q1 FY '24 capex spend: INR 1.8 crores. Major FY '24 capex allocations: - INR 15-20 crores for maintenance capex. - INR 10 crores for overhauling IT infrastructure. - INR 10 crores for expanding physical infrastructure within India. - INR 10 crores for international expansion, including Africa operations. Strategic investment in expanding franchise business deeper into Tier 2+ India. Setting up of JV operations in international markets like Africa, with ongoing team hiring and lab setup. Investments mad

Future growth expectations in sales/revenue/volumes?

Franchise business grew 16% YoY and is expected to sustain similar growth throughout FY '24. Partnerships business aims to recover to about 35%-36% share; overall growth expected around 12%-14%. Focus on deepening franchise presence in Tier 2+ India regions with a targeted test menu. D2C (Direct-to-Consumer) channel growing organically via remarketing and upselling; marketing-led growth model not yet adopted due to high customer acquisition costs. Government contract participation is cautious and focused on areas like TB and infectious diseases, bidding directly as principal. International exp

Future growth expectations in earnings/operating earnings/profits/EPS?

Franchise business showed strong 16% YoY revenue growth; expected to sustain this growth throughout FY '24. Partnership business expected to stabilize at around INR35 crores monthly, with cautious bidding on government contracts. Overall revenue growth guidance for FY '24 is around 12-14%, driven by franchise expansion and partnership stabilization. EBITDA margins for FY '24 are expected to stay around 31% ±1%. Margin expansion potential exists but returning to earlier peak margins (~40%) is unlikely due to increased investments in lab network and quality. Focus on cost control, oper

Current/ Expected Orderbook/ Pending Orders?

Thyrocare mentioned expecting to recoup the partnership business through bidding for new government contracts. These government contracts are bid directly by Thyrocare (as principal), not by partners. Billing risk for these government contracts lies with Thyrocare. The company is being cautious, focusing on government contracts in areas of strength like TB and infectious diseases. No explicit specific figures or quantitative details about the current or expected order book or pending orders were provided in the transcript on page 15.

IN US

Sale is live|00:00:00left today

Thyrocare Technologies LtdQ2 FY23Healthcare Services

Thyrocare Technologies Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹546P/E: 43.9Market Cap: ₹7.4K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 4

Margin

Category 2

Fundraise

N/A

Order

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Franchise business grew 16% YoY and is expected to sustain similar growth throughout FY '24.
→Partnerships business aims to recover to about 35%-36% share; overall growth expected around 12%-14%.
→Focus on deepening franchise presence in Tier 2+ India regions with a targeted test menu.
→D2C (Direct-to-Consumer) channel growing organically via remarketing and upselling; marketing-led growth model not yet adopted due to high customer acquisition costs.
→Government contract participation is cautious and focused on areas like TB and infectious diseases, bidding directly as principal.
→International expansion planned, with operations in Africa expected to start by year-end, aiming to replicate India's low-cost model.
→Price structure changes to slab-based discounts promote volume growth and higher realization per patient.
→Expect margins to hold around 31% (+/-1%) with controlled operating costs.

Margin guidance

Category 2

→Franchise business showed strong 16% YoY revenue growth; expected to sustain this growth throughout FY '24.
→Partnership business expected to stabilize at around INR35 crores monthly, with cautious bidding on government contracts.
→Overall revenue growth guidance for FY '24 is around 12-14%, driven by franchise expansion and partnership stabilization.
→EBITDA margins for FY '24 are expected to stay around 31% ±1%.
→Margin expansion potential exists but returning to earlier peak margins (~40%) is unlikely due to increased investments in lab network and quality.
→Focus on cost control, operating leverage, and investment in quality to support margin improvement.
→New pricing model (pay-for-performance) to sustain revenue and margin growth.
→Esop costs ongoing but non-cash and accounted for; no impact on cash flow or equity dilution.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned new fundraising through debt or equity in the provided text.
→The company currently holds cash of INR 80 crores (both Thyrocare and ESL combined) primarily in debt mutual funds.
→The management has been cautious about bidding for new government contracts to manage billing risk, indicating a conservative financial approach.
→The focus appears to be on organic growth, partnership expansions, and capex investments (~INR 45 crores planned for FY '24), without reliance on new external fundraisings.
→No explicit discussion about equity dilution or new debt issuance was noted in the call excerpts.

Order book

→Thyrocare mentioned expecting to recoup the partnership business through bidding for new government contracts.
→These government contracts are bid directly by Thyrocare (as principal), not by partners.
→Billing risk for these government contracts lies with Thyrocare.
→The company is being cautious, focusing on government contracts in areas of strength like TB and infectious diseases.
→No explicit specific figures or quantitative details about the current or expected order book or pending orders were provided in the transcript on page 15.

Capex plans

Yes

→FY '23 capex was close to INR 40 crores.
→FY '24 capex budgeted around INR 45 crores.
→Q1 FY '24 capex spend: INR 1.8 crores.
→Major FY '24 capex allocations:
→ - INR 15-20 crores for maintenance capex.
→ - INR 10 crores for overhauling IT infrastructure.
→ - INR 10 crores for expanding physical infrastructure within India.
→ - INR 10 crores for international expansion, including Africa operations.
→Strategic investment in expanding franchise business deeper into Tier 2+ India.
→Setting up of JV operations in international markets like Africa, with ongoing team hiring and lab setup.
→Investments made in expanding lab network and quality improvements (e.g., pathologists at each lab).
→Focus on cautious bidding for government contracts directly by Thyrocare, not via partners.

How does Thyrocare Technologies Ltd rank vs peers in Healthcare Services?

Pro feature

1Thyrocare Technologies Ltd

Rev 4Mar 2

See full Healthcare Services sector rankings

Want more stocks like Thyrocare Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio